ReviewCurrent opinion in nephrology and hypertension2009
Association of cystatin C with adverse outcomes.
Review in Current opinion in nephrology and hypertension, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis.Bioscience reports · 2019Pooled it
- Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2011Trial
- High unawareness of kidney dysfunction in European older adults and the importance of early detection through comorbidities.PloS one · 2025Article
- Should Cystatin C eGFR Become Routine Clinical Practice?Biomolecules · 2023Review
- Trends in Passive IoT Biomarker Monitoring and Machine Learning for Cardiovascular Disease Management in the U.S. Elderly Population.Advances in geriatric medicine and research · 2023Article
- Insights into Cognitive Brain Health in Chronic Kidney Disease.Gerontology & geriatrics : research · 2022Article
- Non-linear association of cystatin C and all-cause mortality of heart failure: A secondary analysis based on a published database.Frontiers in cardiovascular medicine · 2022Article
- A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies.Toxicologic pathology · 2021Review
- Novel Filtration Markers for GFR Estimation.EJIFCC · 2017Article
- Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients.Yonsei medical journal · 2017Article
- Biomarkers in chronic kidney disease, from kidney function to kidney damage.World journal of nephrology · 2015Review
- Relationship between Systemic and Cerebral Vascular Disease and Brain Structure Integrity in Normal Elderly Individuals.Journal of Alzheimer's disease : JAD · 2015Article
- Body mass index and preclinical kidney disease in Indian adults aged 40 years and above without chronic kidney disease.Clinical and experimental nephrology · 2014Article
- Comparison of CKD-EPI Cystatin C and Creatinine Glomerular Filtration Rate Estimation Equations in Asian Indians.International journal of nephrology · 2014Article
- Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus.Cardiovascular diabetology · 2013Article
- Kidney Toxicity Induced by 13 Weeks Exposure to the Fruiting Body of Paecilomyces sinclairii in Rats.Toxicological research · 2012Article
- Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus.Lupus · 2012Article
- Measurement of organ structure and function enhances understanding of the physiological basis of frailty: the Cardiovascular Health Study.Journal of the American Geriatrics Society · 2011Article
- Estimating glomerular filtration rate in diabetes using serum cystatin C.The Clinical biochemist. Reviews · 2011Article
- Coffee consumption and cystatin-C-based estimated glomerular filtration rates in healthy young adults: results of a clinical trial.Journal of nutrition and metabolism · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewTo discuss recent studies which have evaluated determinants of cystatin C and to focus on the relationship of cystatin C with mortality, cardiovascular disease (CVD), and noncardiovascular outcomes. RECENT
findingsIn the Chronic Kidney Disease Epidemiology Study cystatin C was associated with demographic characteristics independent of measured glomerular filtration rate (GFR), although this was to a smaller extent than creatinine. In patients with established chronic kidney disease (CKD), cystatin C was strongly and inversely correlated with measured GFR, suggesting that although cystatin C may have other determinants, it is primarily a measure of kidney function. Several cohort studies, particularly in older adults, have now demonstrated that cystatin C is linearly associated with mortality, CVD and non-CVD outcomes, whereas creatinine is primarily associated with risk in individuals with more advanced kidney disease. A recent study has also shown that changes in kidney function as ascertained by cystatin C, even within the relatively normal range, are associated with subsequent CVD and all-cause mortality among older adults. SUMMARY: Cystatin C appears to capture an association of mild kidney disease with increased risk of mortality, CVD and non-CVD outcomes. Future studies should evaluate whether cystatin C can improve medical decision-making and lead to favorable patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.